Progress of diagnosis and treatment of sellar ependymoma

doi:10.3877/cma.j.issn.2095-9141.2023.01.010

Abstract

Abstract:

Sellar ependymoma (SEP) is an extremely rare solid tumor with few case reports. The clinical manifestations and imaging features are similar to non-functional pituitary adenomas. The diagnosis mainly depends on postoperative histopathology. Currently, there are no clinical treatment guidelines, and the treatment method is mainly surgery. This article mainly reviews the etiology, pathogenesis, clinical manifestations, diagnosis, and treatment of SEP based on the current related literature in order to better guide the clinical work.

Key words: Sellar, Ependymoma, Diagnosis

Jiawei He, Liang Zhang, Qi Yang, Chengtian Gao, Zhanxiang Wang. Progress of diagnosis and treatment of sellar ependymoma[J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2023, 09(01): 51-53.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsjcswkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9141.2023.01.010

https://zhsjcswkdzzz.cma-cmc.com.cn/EN/Y2023/V09/I01/51

References 34

[1]	Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016[J]. Neuro Oncol, 2019, 21(Suppl 5): v1-v100. DOI: 10.1093/neuonc/noz150.
[2]	Whipple SG, Savardekar AR, Rao S, et al. Primary tumors of the posterior pituitary gland: a systematic review of the literature in light of the new 2017 World Health Organization classification of pituitary tumors[J]. World Neurosurg, 2021, 145: 148-158. DOI: 10.1016/j.wneu.2020.09.023.
[3]	Shibuya M. Welcoming the new WHO classification of pituitary tumors 2017: revolution in TTF-1-positive posterior pituitary tumors[J]. Brain Tumor Pathol, 2018, 35(2): 62-70. DOI: 10.1007/s10014-018-0311-6.
[4]	Zhao L, Jiang Y, Wang Y, et al. Case report: sellar ependymomas: a clinic-pathological study and literature review[J]. Front Endocrinol (Lausanne), 2021, 12: 551493. DOI: 10.3389/fendo.2021.551493.
[5]	Wang S, Zong W, Li Y, et al. Pituitary ependymoma: a case report and review of the literature[J]. World Neurosurg, 2018, 110: 43-54. DOI: 10.1016/j.wneu.2017.10.134.
[6]	Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114(2): 97-109. DOI: 10.1007/s00401-007-0243-4.
[7]	Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary[J]. Neuro Oncol, 2021, 23(8): 1231-1251. DOI: 10.1093/neuonc/noab106.
[8]	Van Gompel JJ, Koeller KK, Meyer FB, et al. Cortical ependymoma: an unusual epileptogenic lesion[J]. J Neurosurg, 2011, 114(4): 1187-1194. DOI: 10.3171/2010.12.JNS10846.
[9]	Sarkisian SS, Schultz AL. Pituitary ependymoma[J]. U S Armed Forces Med J, 1956, 7(12): 1813-1816.
[10]	Takei Y, Seyama S, Pearl GS, et al. Ultrastructural study of the human neurohypophysis. II. Cellular elements of neural parenchyma, the pituicytes[J]. Cell Tissue Res, 1980, 205(2): 273-287. DOI: 10.1007/BF00234685.
[11]	Scheithauer BW, Swearingen B, Whyte ET, et al. Ependymoma of the sella turcica: a variant of pituicytoma[J]. Hum Pathol, 2009, 40(3): 435-40. DOI: 10.1016/j.humpath.2008.08.013.
[12]	McGuire CS, Sainani KL, Fisher PG. Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study[J]. J Neurosurg, 2009, 110(4): 725-729. DOI: 10.3171/2008.9.JNS08117.
[13]	Parish JM, Bonnin JM, Goodman JM, et al. Intrasellar ependymoma: clinical, imaging, pathological, and surgical findings[J]. J Clin Neurosci, 2015, 22(4): 638-641. DOI: 10.1016/j.jocn.2014.10.026.
[14]	Asa SL, Mete O. What's new in pituitary pathology？[J]. Histopathology, 2018, 72(1): 133-141. DOI: 10.1111/his.13295.
[15]	Kumar PV. Nuclear grooves in ependymoma. Cytologic study of 21 cases[J]. Acta Cytol, 1997, 41(6): 1726-1731. DOI: 10.1159/000333176.
[16]	Belcher R, Chahal HS, Evanson J, et al. Recurrent pituitary ependymoma: a complex clinical problem[J]. Pituitary, 2010, 13(2): 176-182. DOI: 10.1007/s11102-008-0139-x.
[17]	Lee JS, Cho KH, Hong EK, et al. Pituitary ependymoma, 10-year follow-up after partial resection and radiation therapy[J]. Brain Tumor Res Treat, 2017, 5(2): 94-98. DOI: 10.14791/btrt.2017.5.2.94.
[18]	Guerrero-Pérez F, Marengo AP, Vidal N, et al. Primary tumors of the posterior pituitary: a systematic review[J]. Rev Endocr Metab Disord, 2019, 20(2): 219-238. DOI: 10.1007/s11154-019-09484-1.
[19]	Mukhida K, Asa S, Gentili F, et al. Ependymoma of the pituitary fossa. Case report and review of the literature[J]. J Neurosurg, 2006, 105(4): 616-620. DOI: 10.3171/jns.2006.105.4.616.
[20]	刘梦琦,刘有,陈志晔.鞍区室管膜瘤一例[J].中国医学科学院学报, 2019, 41(1): 139-142. DOI: 10.3881/j.issn.1000-503X.10397.
[21]	Thomson S, Chakrabarty A, Marks P. Ependymoma of the neurohypophysis[J]. Br J Neurosurg, 2001, 15(3): 277-278. DOI: 10.1080/026886901750353764.
[22]	Brat DJ, Scheithauer BW, Staugaitis SM, et al. Pituicytoma: a distinctive low-grade glioma of the neurohypophysis[J]. Am J Surg Pathol, 2000, 24(3): 362-368. DOI: 10.1097/00000478-200003000-00004.
[23]	Lukashova-v Zangen I, Kneitz S, Monoranu CM, et al. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival[J]. Acta Neuropathol, 2007, 113(3): 325-337. DOI: 10.1007/s00401-006-0190-5.
[24]	Valassi E, Biller BM, Klibanski A, et al. Clinical features of nonpituitary sellar lesions in a large surgical series[J]. Clin Endocrinol (Oxf), 2010, 73(6): 798-807. DOI: 10.1111/j.1365-2265.2010.03881.x.
[25]	赵冬梅,黄新文,梁爽.鞍区室管膜瘤一例[J].中华放射学杂志, 2010, 44(8): 895. DOI: 10.3760/cma.j.issn.1005-1201.2010.08.028.
[26]	Paulino AC, Wen BC, Buatti JM, et al. Intracranial ependymomas: an analysis of prognostic factors and patterns of failure[J]. Am J Clin Oncol, 2002, 25(2): 117-122. DOI: 10.1097/00000421-200204000-00003.
[27]	Cole TS, Potla S, Sarris CE, et al. Rare thyroid transcription factor 1-positive tumors of the sellar region: Barrow neurological institute retrospective case series[J]. World Neurosurg, 2019, 129: e294-e302. DOI: 10.1016/j.wneu.2019.05.132.
[28]	Nagata Y, Inoshita N, Fukuhara N, et al. Low-grade glioma of the neurohypophysis: clinical characteristics and surgical outcomes[J]. World Neurosurg, 2018, 114: e1225-e1231. DOI: 10.1016/j.wneu.2018.03.180.
[29]	Yoshida K, Toda M, Akiyama T, et al. Combined endoscopic endonasal and video-microscopic transcranial approach with preoperative embolization for a posterior pituitary tumor[J]. World Neurosurg, 2018, 119: 201-208. DOI: 10.1016/j.wneu.2018.07.245.
[30]	Guerrero-Pérez F, Vidal N, Marengo AP, et al. Posterior pituitary tumours: the spectrum of a unique entity. A clinical and histological study of a large case series[J]. Endocrine, 2019, 63(1): 36-43. DOI: 10.1007/s12020-018-1774-2.
[31]	Lefevre E, Bouazza S, Bielle F, et al. Management of pituicytomas: a multicenter series of eight cases[J]. Pituitary, 2018, 21(5): 507-514. DOI: 10.1007/s11102-018-0905-3.
[32]	Zhang Y, Teng Y, Zhu H, et al. Granular cell tumor of the neurohypophysis: 3 cases and a systematic literature review of 98 cases[J]. World Neurosurg, 2018, 118: e621-e630. DOI: 10.1016/j.wneu.2018.07.004.
[33]	Mack SC, Witt H, Piro RM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy[J]. Nature, 2014, 506(7489): 445-450. DOI: 10.1038/nature13108.
[34]	Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary[J]. Acta Neuropathol, 2016, 131(6): 803-820. DOI: 10.1007/s00401-016-1545-1.

Please choose a citation manager

Content to export